# 68Ga-PSMA PET/CT in Prostate Cancer

> **NCT03001869** · PHASE3 · COMPLETED · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 540 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 68Ga-HBED-CC-PSMA PET/CT

## Key facts

- **NCT ID:** NCT03001869
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001869, "68Ga-PSMA PET/CT in Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03001869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*